Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07503795
Starting soon Observational

Outcomes of Definitive Radiotherapy for Bladder Cancer

NCT07503795 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sohag University
Phase
Observational
Started
2026-04-01
Last updated
2026-03-31

Condition(s) studied

Bladder Cancer (BC)

Investigational drug(s) / intervention(s)

Radiotherapy followed by chemotherapy

Radiotherapy followed by chemotherapy: it is observational study for patient recieved defentive radiotherapy

Study summary

this is an observational study for patients with non metastatic bladder cancer recieving local radical radiotherapy with curative intent recieving radical dose of radiotherapy with or without chemosensitizer

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Histologically confirmed urothelial carcinoma or variants; definitive intent radiotherapy Exclusion Criteria: * Palliative radiotherapy only; prior radical cystectomy; or incomplete follow-up data.

Primary outcome measure(s)

  • overall survival, it is defined as time from initiation of treatment till death due to any cause or last date for follow up — one and two year
  • bladder intact events free survival , which is the time from initiation of radical ttt till occurrence of bladder recurrence — one and two year
  • disease free survival , it is time from starting radical ttt till occurrance of 1st recurrence or distant metastasis — one and two years

Trial sites (1)

FacilityCityRegionStatus
Sohag University Hospitals Sohag Egypt

More Sohag University trials in Egypt

Colitis Patterns in Patients With Lower GI Symptoms Starting soon
Zadek Osteotomy for Treatment of Haglund's Syndrome Recruiting
Effects of Dexmedetomidine Combined With Lidocaine Topical Administration on Cough Reflex During Extubation in Thyroidectomy Patient. Active, not recruiting
Toxoplasma Gondii Seroprevalence Among Children With Some Neuropsychiatric Disorders Starting soon
Accuracy of Transabdominal Ultrasound in Predicting Intraperitoneal Adhesions Prior to Laparoscopy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07503795 on ClinicalTrials.gov ↗ ← All trials in Egypt